Survodutide vs mazdutide
Last updated: October 27, 2026 · 5 min read · By the Grey Peptides Editorial Board
- Survodutide and mazdutide work the same way: each activates both the GLP-1 receptor, which curbs appetite, and the glucagon receptor, which raises energy use and acts on the liver 1 2.
- Mazdutide cut weight by 11.0% and 14.0% at 48 weeks in GLORY-1, in Chinese adults 8; survodutide reached 14.9% at 46 weeks in phase 2 3 and 12.2% and 13.0% at 76 weeks in its first phase 3 trial, counting everyone randomised 4.
- There is no head-to-head trial, and the trials differ in population, length and analysis, so the numbers cannot be ranked. As of October 27, 2026, mazdutide is approved in China and survodutide is still in trials 2 1.
Side by side
Survodutide High and mazdutide High belong to the same new class: dual agonists at the GLP-1 and glucagon receptors. GLP-1 activity reduces appetite and improves insulin release; glucagon activity increases energy expenditure and acts on fat in the liver 1. Mazdutide is built on oxyntomodulin, a natural gut hormone that acts on both receptors 2. The table is read from our encyclopedia entries.
| Field | Survodutide | Mazdutide |
|---|---|---|
| Encyclopedia entry | Survodutide Full entry | Mazdutide Full entry |
| Molecule class | Peptide | Peptide |
| Category | Metabolic | Metabolic |
| FDA status | In Clinical Trials | Not FDA Approved |
| Approved elsewhere | None recorded | China (NMPA) |
| Evidence grade | High | High |
| Half-life | Long enough for weekly dosing; not reported in the abstracts we hold | Not reported in the sources read; dosed once weekly |
| Formula | Not stated | Not stated |
| Molecular weight | Not stated | Not stated |
| WADA 2026 | Prohibited (S0 catch-all) | Unsettled (S0 may apply) |
| WADA 2027 | Prohibited (S0 catch-all) | Unsettled (S0 may apply) |
| In one line | A once-weekly glucagon/GLP-1 dual agonist: about 13% weight loss at 76 weeks in phase 3 and MASH improvement in phase 2, but not yet approved anywhere. | The first dual glucagon and GLP-1 agonist approved for weight loss anywhere, by China in June 2025; not approved in the US. |
| Mechanism | Dual agonism at GLP-1 and glucagon receptors. GLP-1 drives insulin release, glucagon suppression during hyperglycemia, gastric emptying delay, and central appetite suppression. Glucagon activation increases hepatic lipolysis, hepatic glucose output during hypoglycemia, and energy expenditure — a combination particularly relevant for liver fat reduction in MASH. | Oxyntomodulin-based dual agonism at GLP-1 and glucagon receptors. GLP-1 drives appetite suppression and glycemic control; glucagon contributes to energy expenditure and hepatic fat reduction. In the GLORY-1 phase 3 trial in Chinese adults, 4 and 6 mg weekly lowered weight 11.0% and 14.0% at 48 weeks (PMID 40421736); in GLORY-2, 9 mg weekly lowered it 16.7% at 60 weeks (PMID 42251595). |
| Sources in the entry | 17 | 15 |
| Study cards | 16 | 13 |
| Dosage page | Dosage page | None |
Survodutide's results
In a phase 2 dose-finding trial in adults with obesity and without diabetes (309 treated with survodutide and 77 with placebo), weight fell by 6.2% at 0.6 mg, 12.5% at 2.4 mg, 13.2% at 3.6 mg and 14.9% at 4.8 mg after 46 weeks, against 2.8% on placebo, in the analysis by planned treatment 3. In the first phase 3 trial, SYNCHRONIZE-1, 725 adults with obesity or overweight and no diabetes lost 12.2% on 3.6 mg and 13.0% on 6.0 mg at 76 weeks against 5.4% on placebo, by the treatment-regimen estimand, which counts everyone randomised; 72.6% and 71.9% lost at least 5%, against 46.3% 4. In people with type 2 diabetes, the SYNCHRONIZE-2 paper reported smaller losses, 8.2% and 9.8% on the two doses by the treatment-regimen estimand against 3.9% on placebo, at 76 weeks 5. Its phase 2 programme also included a trial against semaglutide in 413 adults with type 2 diabetes 6 and a trial in 293 adults with MASH and liver fibrosis, in which steatohepatitis improved without worsening fibrosis in 47%, 62% and 43% on 2.4, 4.8 and 6.0 mg against 14% on placebo 7.
Mazdutide's results
GLORY-1 randomized 610 Chinese adults with obesity or overweight, with an average weight of 87.2 kg and BMI of 31.1, to mazdutide 4 mg, 6 mg or placebo 8. At 32 weeks weight had fallen 10.09% and 12.55% on the two doses, against a 0.45% gain on placebo; at 48 weeks the losses were 11.00% and 14.01%, against a 0.30% gain 8. Side effects led 1.5% and 0.5% to stop the drug, against 1.0% on placebo 8.
Side effects
Both drugs cause the gastrointestinal effects typical of the GLP-1 class, but the trials report them differently. In survodutide's phase 2 trial, adverse events occurred in 91% of people on the drug against 75% on placebo, mostly gastrointestinal (75% against 42%) 3; in SYNCHRONIZE-1, gastrointestinal events affected 80.9% and 89.7% on the two doses against 47.9% on placebo 4. In GLORY-1, side effects led 1.5% and 0.5% of people on the two mazdutide doses to stop, against 1.0% on placebo 8. The survodutide figures count all side effects and the GLORY-1 figures only those that ended treatment, so they cannot be set against each other.
Why the numbers cannot be ranked
It is tempting to set 13.0% against 14.0% and call mazdutide the stronger drug. The trials do not allow it. Both figures count everyone randomised, but GLORY-1 enrolled Chinese adults with an average BMI of 31.1 and ran for 48 weeks 8, while SYNCHRONIZE-1 enrolled adults with an average BMI of 37.9 and ran for 76 weeks 4. The placebo groups also behaved differently: a 0.30% gain in GLORY-1 against a 5.4% loss, with lifestyle counselling, in SYNCHRONIZE-1. Only a head-to-head trial, which has not been run, would settle which is stronger.
What the trials do show is that both drugs lowered weight well beyond placebo, and survodutide's phase 2 trial in MASH points to the liver as a second use being tested 7. Our semaglutide vs liraglutide page shows what a genuine head-to-head comparison looks like.
Status as of October 27, 2026
Mazdutide was approved in China by the National Medical Products Administration on June 27, 2025, mainly on GLORY-1, and is not approved in the US 2; survodutide is in clinical trials and not approved anywhere 1. Our SYNCHRONIZE-1 report and the SYNCHRONIZE-2 report follow survodutide's phase 3 programme.
Frequently asked questions
Which works better, survodutide or mazdutide?
No trial has compared them. Their separate trials differ in population, length and analysis, so the headline numbers (13.0% for survodutide 6.0 mg at 76 weeks, 14.0% for mazdutide 6 mg at 48 weeks) cannot be ranked.
Is mazdutide approved?
In China, yes, by the National Medical Products Administration, on June 27, 2025. As of October 27, 2026 it is not approved in the US.
How do they differ from semaglutide?
Both add glucagon-receptor activity to the GLP-1 activity that semaglutide has alone, which raises energy use and acts on liver fat.
Related on Grey Peptides
Sources
- Grey Peptides encyclopedia entry for survodutide: mechanism, approval status (investigational, not approved anywhere as of September 27, 2026) and study cards; read October 27, 2026. Entry
- Grey Peptides encyclopedia entry for mazdutide: oxyntomodulin-based mechanism and approval status (approved by China's NMPA on June 27, 2025; not approved in the US); read October 27, 2026. Entry
- le Roux, C. W., Steen, O., Lucas, K. J., et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol, 12(3), 162-173. PMID: 38330987
- le Roux, C. W., Wharton, S., Startseva, E., et al. (2026). Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med, 395(8), 776-787. PMID: 42253238
- Wharton, S., le, R., Startseva, E., et al. (2026). Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. PMID: 42820639
- Blüher, M., Rosenstock, J., Hoefler, J., et al. (2024). Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia, 67(3), 470-482. PMID: 38095657
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med, 391(4), 311-319. PMID: 38847460
- Ji, L., Jiang, H., Bi, Y., et al. (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med, 392(22), 2215-2225. PMID: 40421736
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead